Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 193

Results For "EU"

5723 News Found

Concord Biotech successfully completes Russian GMP inspection at its API facility
Drug Approval | July 27, 2025

Concord Biotech successfully completes Russian GMP inspection at its API facility

The inspection was conducted from July 22-25, 2025


Dr. Reddy’s infuses Rs. 565 crore in its Russian subsidiary
News | July 27, 2025

Dr. Reddy’s infuses Rs. 565 crore in its Russian subsidiary

The company has made an investment of Rs. 565.40 crore in DRL Russia for a total equity stake of 45.19%


48 projects approved under PLI Scheme for promotion of domestic manufacturing of critical KSMs/DIs/APIs
Policy | July 24, 2025

48 projects approved under PLI Scheme for promotion of domestic manufacturing of critical KSMs/DIs/APIs

The scheme aims to avoid disruption in supply of critical active pharmaceutical ingredients (APIs) used to make critical drugs


NATCO Pharma API unit in Mekaguda receives EIR from USFDA
Drug Approval | July 24, 2025

NATCO Pharma API unit in Mekaguda receives EIR from USFDA

The company received one observation in the Form-483


Zydus receives tentative approval from USFDA for Ibrutinib tablets
Drug Approval | July 24, 2025

Zydus receives tentative approval from USFDA for Ibrutinib tablets

Ibrutinib tablets will be produced at Zydus Lifesciences Ltd (SEZ), Ahmedabad


Akums launches high-strength Paracetamol oral suspension 500mg/5ml
News | July 23, 2025

Akums launches high-strength Paracetamol oral suspension 500mg/5ml

Akums bridges the long-standing gap between paediatric syrups and conventional tablet formats


Torrent Pharma launches nutrition supplement powder Shelcal Total
News | July 23, 2025

Torrent Pharma launches nutrition supplement powder Shelcal Total

Shelcal Total marks the brand’s evolution into a modern, consumer-focused nutrition portfolio


AstraZeneca plans to invest $50 billion in US by 2030
News | July 22, 2025

AstraZeneca plans to invest $50 billion in US by 2030

Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US


Sarepta refuses to comply with FDA request to stop shipping gene therapy Elevidys
Drug Approval | July 21, 2025

Sarepta refuses to comply with FDA request to stop shipping gene therapy Elevidys

FDA requests Sarepta Therapeutics to suspend distribution of Elevidys and places clinical trials on hold for multiple gene therapy products following 3 deaths